SHAREHOLDER ALERT: CEMI CODX KL: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
Back to Newsroom
Mentioned in this Article

SHAREHOLDER ALERT: CEMI CODX KL: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines

Friday, August 14, 2020 3:55 PM
Share this article now
Topic:
Lawsuits

NEW YORK, NY / ACCESSWIRE / August 14, 2020 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss, you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you.

Chembio Diagnostics, Inc. (NASDAQ:CEMI)

If you suffered a loss, contact us at http://www.wongesq.com/pslra-1/chembio-diagnostics-inc-loss-submission-form?prid=8589&wire=1
Lead Plaintiff Deadline: August 17, 2020
Class Period: March 12, 2020 - June 16, 2020

According to the filed complaint, defendants engaged in a scheme to deceive the market and a course of conduct that artificially inflated Chembio's stock price and operated as a fraud or deceit by misrepresenting the efficacy of the Company's Dual Path Platform ("DPP") COVID-19 test. Defendants allegedly achieved this by making false statements about Chembio's DPP COVID-19 test, although they knew or at least recklessly disregarded that there were material performance concerns with the test. When defendants' prior misrepresentations were disclosed and became apparent to the market, the price of Chembio stock fell precipitously as the prior artificial inflation came out of Chembio's stock price.

Co-Diagnostics, Inc. (NASDAQ:CODX)

If you suffered a loss, contact us at http://www.wongesq.com/pslra-1/co-diagnostics-inc-loss-submission-form?prid=8589&wire=1
Lead Plaintiff Deadline: August 17, 2020
Class Period: February 25, 2020 - May 15, 2020

According to the filed complaint, Co-Diagnostics and its directors and officers (including PhD-level scientists who should know better) made continual, knowing, and willful misstatements about the Company's main product, a Covid-19 diagnostic test. These misstatements had the effect of pumping up the price of Co-Diagnostics' stock, while Company officers and directors exercised low-priced options and dumped their stock into the market. Co-Diagnostics' fraudulent misstatements displayed a disregard for basic scientific principles and caused investors to lose millions of dollars.

Kirkland Lake Gold Ltd. (NYSE:KL)

If you suffered a loss, contact us at http://www.wongesq.com/pslra-1/kirkland-lake-gold-ltd-loss-submission-form?prid=8589&wire=1
Lead Plaintiff Deadline: August 28, 2020
Class Period: January 8, 2018 - November 25, 2019

Allegations against KL include that: (i) Kirkland lacked adequate internal controls over financial reporting, especially as it relates to its projections of risks, reserve grade, and all-in sustaining costs; (ii) as a result of the known, but undisclosed, impending acquisition of Detour, the Company's projections relating to its risks, reserve grade, and all-in sustaining costs were false and misleading; (iii) the Company's financial statements and projections were not fairly presented in conformity with International Financial Reporting Standards; (iv) based on the foregoing, Defendants lacked a reasonable basis for their positive statements about the Company's business, operations, and prospects and/or lacked a reasonable basis and omitted material facts.

To learn more, contact Vincent Wong, Esq. either via email [email protected] or by telephone at 212.425.1140.

Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: [email protected]

SOURCE: The Law Offices of Vincent Wong

The Law Offices of Vincent Wong
Exchange:
Ticker:
NASDAQ
CEMI
$7.51
$6.68
Back to Newsroom
Copyright 2020 © ACCESSWIRE. All rights reserved. Privacy Policy  |  Terms and Conditions
Drop us a line: